ERBB2 and breast cancer: Although it is necessary to minimize possible adverse effects, which can be predicted by referring to the phenotypes of inherited mitochondrial disorders caused by mutations of CI‐encoding genes [51], cancer therapy targeting NAD+‐regenerating CI activity would be a promising approach, especially HR(+)/HER2(−) breast cancer, and contribute to better patient prognosis.